Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2009

View Archived Issues

New data demonstrate potential of GLP-1 analogues for neurodegenerative diseases

Baminercept is safe but has no apparent efficacy in phase Ib trials in RA

LX-2931 is safe in combination with methotrexate in patients with stable RA

Antisense oligonucleotides targeting huntingtin show promise for the treatment of HD

Amura describes cathepsin S inhibitors for the treatment of RA

Tubulin polymerization inhibitors for cancer therapy presented by U.S. scientists

Novel MEK inhibitor G-573 tested in tumor xenograft models

AMT and Progenika to develop LPLchip to diagnose lipoprotein lipase deficiency

BioPorto reports technical data of NGAL diagnostic test for acute kidney injury

BioMerieux launches MRSA screening tool

Thermo Fisher Scientific launches new biomarker test for heart attack

Morphotek enters into licensing agreement with Centocor for anticancer therapeutic antibody

Sunesis completes enrollment in voreloxin trial in acute myeloid leukemia

AcelRx completes end-of-phase II meeting for ARX-01 analgesic

UCB reports results from third quarter of 2009

Shire reports tolerability and clinical effects of Daytrana in adolescents with ADHD

HGS and GSK report results for second of two phase III Benlysta trials in SLE

Lundbeck starts clinical phase IIa trial of Lu-AA24493 in Friedreich's ataxia

Byetta approved for expanded use as first-line treatment for type 2 diabetes

FDA issues complete response letter regarding Schering-Plough's sBLA for Pegintron

Solasia completes phase I trial of Sancuso for chemotherapy-induced nausea

Geron and FDA agree on conditions to lift clinical hold on phase I trial of GRNOPC1

ATLAS I and II data show efficacy of telavancin in cellulitis and infected ulcers

Novel hybrid peptide vaccine is safe and immunogenic in phase I trial in prostate cancer

M1 receptor agonists for the treatment of pain claimed by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...